Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Capecitabine, Cyclophosphamide, Lapatinib, and Trastuzumab in HER2+ Metastatic Breast Cancer
NCT01873833Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- Jul 2013
- Primary completion
- Mar 2021
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, cyclophosphamide, lapatinib, trastuzumab in HER2-positive breast cancer, sponsored by University of Southern California. Started Jul 2013; status: terminated.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01873833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01873833.